Health knowledge made personal
Join this community!
› Share page:
Search posts:

Votrient for sarcoma

Posted May 07 2011 12:00am
Pazopanib, brand name Votrient,  is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), and KIT. Inhibitors of VEGFR like pazopanib (Votrient, GlaxoSmithKline), show activity against leiomyosarcoma, synovial sarcoma and other sarcomas including those of vascular origin. There is one supportive phase II study form EORTC. It concluded: “Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types.”


Pazopanib is being investigated in a large randomized placebo-controlled phase III study, which has recently completed accrual and has survival as its endpoint. The study has been expanded in order to ensure that enough events will be observed to determine whether angiogenesis inhibition can prolong survival in patients with chemotherapy-refractory advanced sarcoma: A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy (PALETTE), NCT00753688.


Sleijfer, S.; Ray-Coquard, I.; Papai, Z.; Le Cesne, A.; Scurr, M.; Schoffski, P.; Collin, F.; Pandite, L. et al. (2009). "Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients with Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)" . Journal of Clinical Oncology 27 (19): 3126


Post a comment
Write a comment:

Related Searches